BRPI1007721A2 - composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo - Google Patents
composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduoInfo
- Publication number
- BRPI1007721A2 BRPI1007721A2 BRPI1007721A BRPI1007721A BRPI1007721A2 BR PI1007721 A2 BRPI1007721 A2 BR PI1007721A2 BR PI1007721 A BRPI1007721 A BR PI1007721A BR PI1007721 A BRPI1007721 A BR PI1007721A BR PI1007721 A2 BRPI1007721 A2 BR PI1007721A2
- Authority
- BR
- Brazil
- Prior art keywords
- rotavirus
- inducing
- individual
- immune response
- vaccine composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12361—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17739309P | 2009-05-12 | 2009-05-12 | |
| PCT/US2010/034537 WO2010132561A2 (en) | 2009-05-12 | 2010-05-12 | New human rotavirus strains and vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1007721A2 true BRPI1007721A2 (pt) | 2016-02-16 |
| BRPI1007721B1 BRPI1007721B1 (pt) | 2020-04-28 |
Family
ID=43085559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007721A BRPI1007721B1 (pt) | 2009-05-12 | 2010-05-12 | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US8822192B2 (pt) |
| EP (2) | EP3427750A1 (pt) |
| CN (2) | CN102695522B (pt) |
| AU (1) | AU2010249103B2 (pt) |
| BR (1) | BRPI1007721B1 (pt) |
| CA (3) | CA3121654A1 (pt) |
| ES (1) | ES2723776T3 (pt) |
| WO (1) | WO2010132561A2 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2566527T3 (es) | 2007-09-04 | 2016-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Inactivación térmica de rotavirus |
| EP3427750A1 (en) | 2009-05-12 | 2019-01-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | New human rotavirus strains and vaccines |
| BR112015004085A2 (pt) | 2012-08-27 | 2017-08-08 | Murdoch Childrens Res Inst | método para cultivar uma cepa de rotavírus (rv); método para gerar uma rv3 atenuada em células vero; rv3 adaptada à vero isolada; composição de rv morto ou vivo atenuado; método para vacinar um indivíduo humano contra infecção por rv; método para tratar um indivíduo humano com uma infecção por rv ou em risco de desenvolver uma infecção ou reinfecção por rv; uso da rv3 de vero; anticorpo isolado; e método para detectar ou monitorar a rv3 de vero |
| CN103316336B (zh) * | 2013-05-31 | 2015-01-28 | 北京科兴中维生物技术有限公司 | 一种适于口服的轮状病毒疫苗 |
| CN112724207A (zh) * | 2015-05-21 | 2021-04-30 | 厦门大学 | 截短的轮状病毒vp4蛋白及其用途 |
| CN108431214B (zh) | 2015-10-05 | 2022-03-01 | 美国政府(由卫生和人类服务部的部长所代表) | 人轮状病毒g9p[6]毒株和作为疫苗的用途 |
| EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
| CN106916791B (zh) * | 2015-12-25 | 2021-05-04 | 中国医学科学院医学生物学研究所 | 人轮状病毒毒种ztr-18毒株及其分离，培养及鉴定 |
| UA129115C2 (uk) * | 2016-08-26 | 2025-01-22 | Серум Інстітьют Оф Індія Прайвет Лімітед | Комбінована вакцина |
| WO2020254535A1 (en) * | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
| CN113480617A (zh) * | 2021-07-09 | 2021-10-08 | 山东威高利彤生物制品有限公司 | 轮状病毒毒株及其作为疫苗的用途 |
| CN114940706B (zh) * | 2022-04-20 | 2023-08-15 | 中国疾病预防控制中心病毒病预防控制所 | 一种人轮状病毒毒株、分离培养方法、鉴定及用途 |
| CN117899207A (zh) * | 2023-12-12 | 2024-04-19 | 中国医学科学院医学生物学研究所 | 一种轮状病毒mRNA疫苗及其制备方法和应用 |
| CN118345054B (zh) * | 2024-04-07 | 2025-03-04 | 兰州生物制品研究所有限责任公司 | 一种人-羊轮状病毒基因重配减毒株及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626851A (en) * | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
| ATE170081T1 (de) | 1990-11-16 | 1998-09-15 | Childrens Hosp Medical Center | Humane rotativen, impfstoffe und methoden |
| US6780630B1 (en) | 1992-07-10 | 2004-08-24 | Baylor College Of Medicine | Parenteral immunization against rotavirus |
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US5773009A (en) | 1994-04-15 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Rotavirus strain G9P11 |
| WO1996001651A1 (en) * | 1994-07-11 | 1996-01-25 | The Government Of The United States Of America, Represented By The Department Of Health And Human Services | Attenuated human rotavirus vaccine |
| US6673355B1 (en) | 1995-06-14 | 2004-01-06 | Baylor College Of Medicine | Rotavirus enterotoxin NSP4 and methods of using same |
| US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US6506385B1 (en) | 1998-04-17 | 2003-01-14 | Embrex, Inc. | Live vaccines and methods of treatment therewith |
| WO2000006196A2 (en) | 1998-07-28 | 2000-02-10 | The Government Of The United States Of America, Represented By The Department Of Health And Human Services | Multivalent human-bovine rotavirus vaccine |
| US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| AU767885B2 (en) | 1999-08-17 | 2003-11-27 | Smithkline Beecham Biologicals (Sa) | Vaccine |
| US20030166139A1 (en) | 2001-07-20 | 2003-09-04 | Choi Anthony H. | Rotavirus VP6 subunit |
| GB0414787D0 (en) | 2004-07-01 | 2004-08-04 | Glaxosmithkline Biolog Sa | Method |
| WO2006007555A2 (en) | 2004-07-01 | 2006-01-19 | Children's Medical Center Corporation ¨ | Rotavirus antigens |
| GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| US20090136545A1 (en) * | 2005-07-11 | 2009-05-28 | Yasutaka Hoshino | Porcine rotavirus reassortant compositions |
| ES2566527T3 (es) * | 2007-09-04 | 2016-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Inactivación térmica de rotavirus |
| EP3427750A1 (en) * | 2009-05-12 | 2019-01-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | New human rotavirus strains and vaccines |
-
2010
- 2010-05-12 EP EP18188577.3A patent/EP3427750A1/en active Pending
- 2010-05-12 AU AU2010249103A patent/AU2010249103B2/en active Active
- 2010-05-12 BR BRPI1007721A patent/BRPI1007721B1/pt active IP Right Grant
- 2010-05-12 CN CN201080031412.1A patent/CN102695522B/zh active Active
- 2010-05-12 CA CA3121654A patent/CA3121654A1/en active Pending
- 2010-05-12 ES ES10775467T patent/ES2723776T3/es active Active
- 2010-05-12 CA CA2763359A patent/CA2763359C/en active Active
- 2010-05-12 EP EP10775467.3A patent/EP2429577B1/en active Active
- 2010-05-12 CA CA3121471A patent/CA3121471A1/en not_active Abandoned
- 2010-05-12 WO PCT/US2010/034537 patent/WO2010132561A2/en not_active Ceased
- 2010-05-12 US US13/320,095 patent/US8822192B2/en active Active
- 2010-07-12 CN CN201610861616.7A patent/CN106421772A/zh active Pending
-
2014
- 2014-08-18 US US14/461,663 patent/US9498526B2/en active Active
-
2016
- 2016-07-01 US US15/200,837 patent/US9974851B2/en active Active
-
2018
- 2018-04-18 US US15/956,662 patent/US10500269B2/en active Active
-
2019
- 2019-11-01 US US16/672,168 patent/US11065327B2/en active Active
-
2021
- 2021-06-16 US US17/349,639 patent/US11786589B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2429577B1 (en) | 2019-01-30 |
| US20180236060A1 (en) | 2018-08-23 |
| CN102695522B (zh) | 2016-10-19 |
| EP3427750A1 (en) | 2019-01-16 |
| CN102695522A (zh) | 2012-09-26 |
| CA2763359C (en) | 2021-07-27 |
| US9974851B2 (en) | 2018-05-22 |
| US20200054735A1 (en) | 2020-02-20 |
| BRPI1007721B1 (pt) | 2020-04-28 |
| US10500269B2 (en) | 2019-12-10 |
| AU2010249103A1 (en) | 2012-01-12 |
| US11065327B2 (en) | 2021-07-20 |
| CA3121654A1 (en) | 2010-11-18 |
| AU2010249103B2 (en) | 2015-02-26 |
| EP2429577A4 (en) | 2013-11-06 |
| US8822192B2 (en) | 2014-09-02 |
| US20170173144A1 (en) | 2017-06-22 |
| CA2763359A1 (en) | 2010-11-18 |
| WO2010132561A2 (en) | 2010-11-18 |
| WO2010132561A3 (en) | 2011-06-16 |
| US20210308254A1 (en) | 2021-10-07 |
| WO2010132561A8 (en) | 2011-03-03 |
| US9498526B2 (en) | 2016-11-22 |
| CN106421772A (zh) | 2017-02-22 |
| US20150079122A1 (en) | 2015-03-19 |
| US11786589B2 (en) | 2023-10-17 |
| US20120121629A1 (en) | 2012-05-17 |
| CA3121471A1 (en) | 2010-11-18 |
| EP2429577A2 (en) | 2012-03-21 |
| ES2723776T3 (es) | 2019-09-02 |
| AU2010249103A2 (en) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007721A2 (pt) | composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo | |
| BR112012019757A2 (pt) | composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular | |
| BR112013014712A2 (pt) | método para induzir uma resposta imune contra um antígeno de filovírus em um indivíduo | |
| BRPI0920283A2 (pt) | composição e método para induzir resposta imunológica humoral | |
| BRPI0920282A2 (pt) | composição e método para induzir resposta imunológica humoral | |
| BR112012033790A2 (pt) | cápsula,dispositivo e método para preparar uma bebida por extração | |
| BR112013030321A2 (pt) | composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv. | |
| BRPI1012811A2 (pt) | vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune | |
| BR112014004430A8 (pt) | extrato de levedura, método para intensificar um sabor de alimento, e, agente intensificador de sabor de alimento | |
| BRPI0905725A2 (pt) | vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo | |
| BR112013020875A2 (pt) | método para indução de uma resposta imune específica para um imunógeno em um indivíduo. | |
| BRPI0923448A2 (pt) | vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina. | |
| IL228648A0 (en) | A capsule containing an activation factor, a method and a device for processing the capsule | |
| BRPI1008643A2 (pt) | Recreio alimentício cremoso, e, método para formar um recheio alimentício cremoso | |
| BR112012001967A2 (pt) | micro-organismo, e, método e composição para suprimir a fusariose em uma planta de cereal | |
| ZA200905952B (en) | Lyophilized preparation comprising influenza vaccine,and method for preparation thereof | |
| BRPI0810865A2 (pt) | antígenos de tripanossoma, composições vacinais, e métodos relacionados | |
| EP2477649A4 (en) | VACCINE AGAINST CHOLERA AND ENTEROTOXY E. coli (ETEC) -DIARRHÖE | |
| PT2658570T (pt) | Composições e métodos vacinais contra o vírus da diarreia viral bovina tipo 1b | |
| EP2760419A4 (en) | PERSONAL CARE COMPOSITION COMPRISING A NATURAL EMULSIFIER SYSTEM THAT DOES NOT CONTAIN SILICONE EMULSIFYING AGENT | |
| EP2760420A4 (en) | PERSONAL CARE COMPOSITION COMPRISING A NATURAL EMULSIFIER SYSTEM THAT DOES NOT CONTAIN SILICONE EMULSIFYING AGENT | |
| ZA201309516B (en) | Protein matrix vaccine compositions including polycations | |
| BRPI0820258A2 (pt) | composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduo | |
| BR112014015527A2 (pt) | cepa de lactobacillus mucosae, método para a obtenção de uma cepa e de uma fração de célula, composição e método para a obtenção de uma composição | |
| BR112014010515A2 (pt) | método para controlar uma população de erva daninha em um ambiente, e, composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2010, OBSERVADAS AS CONDICOES LEGAIS. |